Phaseline

Companies › Tagworks Pharmaceuticals

Tagworks Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TGW101
Chemically cleavable diabody drug conjugate (TGW101-ADC) with chemical trigger (TRG001)
–Phase 1Advanced Solid TumorsOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06959706TGW101Phase 1Advanced Solid TumorsOncologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.